Pediatric rheumatology

Predictive utility of anti-neutrophil cytoplasmic antibody (ANCA) positivity and antigen specificity in the assessment of kidney disease in paediatric-onset small vessel vasculitis

RMD OpenPublished Retrospective cohort study

Authors' conclusion

The results of this study suggest important paediatric-specific differences in the predictive value of ANCA compared with adult patients that should be considered when making treatment decisions in this population.

Study context

Population
Children and adolescents with small vessel vasculitis, ARChiVe/Paediatric Vasculitis Initiative registry
Participants
406 children
Exposure
MPO-ANCA vs PR3-ANCA vs ANCA-negative paediatric-onset small vessel vasculitis
  • ANCA-negativen = 41
  • MPO-ANCAn = 129
  • PR3-ANCAn = 236reference
Outcome
Overall and kidney-specific disease activity at diagnosis and outcomes between 1 and 2 years
Methodological detailsregistry-based (ARChiVe/Paediatric Vasculitis Initiative), generalised linear models
  • Registry-based (ARChiVe/Paediatric Vasculitis Initiative)
  • Generalised linear models

Main finding

As reported in the abstract

onset
MPO-ANCA vs PR3-ANCAOdds ratio (95% CI)P value
Kidney involvement
2.4(1.3–4.7)
P = 0.008
Severe kidney dysfunction (KDIGO stages 4-5)
6.04(2.77–13.57)
P < 0.001

Observational data: associations, not effects.

Further findings

OutcomeP value
Improvement in kidney function (improved KDIGO category) in similarly severe kidney disease at onset · within 1 yearMPO-ANCA vs PR3-ANCA · MPO-ANCA more likely to improveP < 0.001

Inactive disease, improvement, damage by 1 year

No significant differences by ANCA positivity or specificity: inactive disease
≈68%
Improvement
≥87%
Damage
≈58%

Relapse · between 1 and 2 years after diagnosis

No significant differences in likelihood of relapse
≈11%

Original publication

Predictive utility of ANCA positivity and antigen specificity in the assessment of kidney disease in paediatric-onset small vessel vasculitis. RMD Open. Published 17 June 2024. doi:10.1136/rmdopen-2024-004315

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.